子宮内膜症 - 市場考察、疫学、市場予測（2032年）

主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）の子宮内膜症の市場規模は、2021年に最大19億2,000万米ドルであり、調査期間中（2019年～2032年）に成長が予測されています。

当レポートでは、子宮内膜症の主要7市場について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。

目次

第1章 主要考察

第2章 レポートのイントロダクション

第3章 子宮内膜症市場の概要

• 子宮内膜症の市場シェア分布（2019年）
• 子宮内膜症の市場シェア分布（2032年）

第4章 子宮内膜症のエグゼクティブサマリー

• 重要な出来事

第5章 疫学と市場調査手法

第6章 疾患の背景と概要

• イントロダクション
• 子宮内膜症の分類
• 子宮内膜症の種類
• 子宮内膜症の病因
• 子宮内膜症の危険因子
• 子宮内膜症の症状
• 子宮内膜症の合併症
• 子宮内膜症の診断
• 子宮内膜症の治療
• 結論

第7章 疫学と患者数

• 主な調査結果
• 前提条件と理論的根拠：主要7市場
• 主要7市場の疫学シナリオ
• 米国の疫学シナリオ
• 欧州4ヶ国・英国の疫学シナリオ
• 日本の疫学シナリオ

第8章 ペイシェントジャーニー

第9章 子宮内膜症の臨床試験における主な評価項目

第10章 上市済みの治療法

第11章 新たな治療法

第12章 子宮内膜症：主要7市場の分析

• 主な調査結果
• 市場の見通し
• 主な市場の予測の前提条件
• 主要7市場の市場規模
  • 主要7市場の子宮内膜症の総市場規模
  • 主要7市場の子宮内膜症の市場規模：治療法別
• 米国の市場規模
  • 米国の子宮内膜症の子宮内膜症の総市場規模
  • 米国の子宮内膜症の子宮内膜症の市場規模：治療法別
• 欧州4ヶ国・英国の市場規模
  • 欧州4ヶ国・英国の子宮内膜症の総市場規模
  • 欧州4ヶ国・英国の子宮内膜症の市場規模：治療法別
• 日本の市場規模
  • 日本の子宮内膜症の総市場規模
  • 日本の子宮内膜症の市場規模：治療法別

第13章 市場参入と償還

第14章 KOLの見解

第15章 SWOT分析

第16章 アンメットニーズ

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

List of Tables

• Table 1: Summary of endometriosis, Market, Epidemiology, and Key Events (2019-2032)
• Table 2: Prevalent Cases of Endometriosis in the 7MM, in millions (2019-2032)
• Table 3: Diagnosed Prevalent Cases of Endometriosis in the 7MM, in millions (2019-2032)
• Table 4: Age-specific Diagnosed Prevalent Cases of Endometriosis in the 7MM, in millions (2019-2032)
• Table 5: Diagnosed Prevalent Cases of Endometriosis by Pain Severity in the 7MM, in millions (2019-2032)
• Table 6: Total Treated Cases of Endometriosis in the 7MM, in millions (2019-2032)
• Table 7: Prevalent Cases of Endometriosis in the US, in millions (2019-2032)
• Table 8: Diagnosed Prevalent Cases of Endometriosis in the US, in millions (2019-2032)
• Table 9: Age-specific Diagnosed Prevalent Cases of Endometriosis in the US, in millions (2019-2032)
• Table 10: Diagnosed Prevalent Cases of Endometriosis by Pain Severity in the US, in millions (2019-2032)
• Table 11: Total Treated Cases of Endometriosis in the US, in millions (2019-2032)
• Table 12: Prevalent Cases of Endometriosis in EU4 and the UK, in millions (2019-2032)
• Table 13: Diagnosed Prevalent Cases of Endometriosis in EU4 and the UK, in millions (2019-2032)
• Table 14: Age-specific Diagnosed Prevalent Cases of Endometriosis in EU4 and the UK, in millions (2019-2032)
• Table 15: Diagnosed Prevalent Cases of Endometriosis by Pain Severity in EU4 and the UK, in millions (2019-2032)
• Table 16: Total Treated Cases of Endometriosis in EU4 and the UK, in millions (2019-2032)
• Table 17: Prevalent Cases of Endometriosis in Japan (2019-2032)
• Table 18: Diagnosed Prevalent Cases of Endometriosis in Japan, in millions (2019-2032)
• Table 19: Age-specific Diagnosed Prevalent Cases of Endometriosis in Japan, in millions (2019-2032)
• Table 20: Diagnosed Prevalent Cases of Endometriosis by Pain Severity in Japan, in millions (2019-2032)
• Table 21: Total Treated Cases of Endometriosis in Japan, in millions (2019-2032)
• Table 22: Proportion of Responders for Dysmenorrhea and Nonmenstrual Pelvic Pain at Month 3 in Studies EM-1 and EM-2, Using the Endometriosis Daily Pain Impact Scale
• Table 23: ORILISSA, Clinical Trial Description, 2022
• Table 24: Proportions of Dysmenorrhea and Nonmenstrual Pelvic Pain Responders at Week 24
• Table 25: MYFEMBREE, Clinical Trial Description, 2022
• Table 26: Change from Baseline In Maximum VAS Score for 28 days Before the end of the Administration
• Table 27: Comparison of Emerging Drugs Under Development
• Table 28: ORIAHNN, Clinical Trial Description, 2022
• Table 29: Linzagolix, Clinical Trial Description, 2022
• Table 30: OVAREST, Clinical Trial Description, 2022
• Table 31: HMI-115, Clinical Trial Description, 2022
• Table 32: TU2670, Clinical Trial Description, 2022
• Table 33: OG-6219, Clinical Trial Description, 2022
• Table 34: Market Size of Endometriosis in the 7MM, USD million (2019-2032)
• Table 35: Market Size of Endometriosis by Therapies in the 7MM, USD million (2019-2032)
• Table 36: Market Size of Endometriosis in the US, USD million (2019-2032)
• Table 37: Market Size of Endometriosis by Therapies in the US, USD million (2019-2032)
• Table 38: Market Size of Endometriosis in EU4 and the UK, in USD million (2019-2032)
• Table 39: Market Size of Endometriosis by Therapies in EU4 and the UK, USD million (2019-2032)
• Table 40: Market Size of Endometriosis in Japan, USD million (2019-2032)
• Table 41: Market Size of Endometriosis by Therapies in Japan, USD million (2019-2032)
• Table 42: Key HTA Decisions

List of Figures

• Figure 1: Epidemiology and Market Methodology
• Figure 2: Endometrial Tissue Growth on the Ovaries and Fallopian Tubes
• Figure 3: ENZIAN classification with potentially affected organs and compartments.
• Figure 4: Different Types of Endometriosis
• Figure 5: Potential Pathways for the Pathogenesis and Pathophysiological Features of Pelvic Endometriosis
• Figure 6: Different Risk Factors That Account for the Pathogenesis of Eutopic and Ectopic Endometriosis
• Figure 7: Symptoms of Endometriosis
• Figure 8: Gynecologic and Systemic Comorbidities in Patients With Endometriosis and Their Effect on the Quality of Life
• Figure 9: Diagnostic Procedures of Endometriosis
• Figure 10: Diagnostic Algorithm of Endometriosis
• Figure 11: Treatment Algorithm Endometriosis-associated Pain
• Figure 12: Treatment Algorithm Endometriosis-associated Infertility
• Figure 13: Prevalent Cases of Endometriosis in the 7MM (2019-2032)
• Figure 14: Diagnosed Prevalent Cases of Endometriosis in the 7MM (2019-2032)
• Figure 15: Age-specific Diagnosed Prevalent Cases of Endometriosis in the 7MM (2019-2032)
• Figure 16: Diagnosed Prevalent Cases of Endometriosis by Pain Severity in the 7MM (2019-2032)
• Figure 17: Total Treated Cases of Endometriosis in the 7MM (2019-2032)
• Figure 18: Prevalent Cases of Endometriosis in the US (2019-2032)
• Figure 19: Diagnosed Prevalent Cases of Endometriosis in the US (2019-2032)
• Figure 20: Age-specific Diagnosed Prevalent Cases of Endometriosis in the US (2019-2032)
• Figure 21: Diagnosed Prevalent Cases of Endometriosis by Pain Severity in the US (2019-2032)
• Figure 22: Total Treated Cases of Endometriosis in the US (2019-2032)
• Figure 23: Prevalent Cases of Endometriosis in EU4 and the UK (2019-2032)
• Figure 24: Diagnosed Prevalent Cases of Endometriosis in EU4 and the UK (2019-2032)
• Figure 25: Age-specific Diagnosed Prevalent Cases of Endometriosis in EU4 and the UK (2019-2032)
• Figure 26: Diagnosed Prevalent Cases of Endometriosis by Pain Severity in EU4 and the UK (2019-2032)
• Figure 27: Total Treated Cases of Endometriosis in EU4 and the UK (2019-2032)
• Figure 28: Prevalent Cases of Endometriosis in Japan (2019-2032)
• Figure 29: Diagnosed Prevalent Cases of Endometriosis in Japan (2019-2032)
• Figure 30: Age-specific Diagnosed Prevalent Cases of Endometriosis in Japan (2019-2032)
• Figure 31: Diagnosed Prevalent Cases of Endometriosis by Pain Severity in Japan (2019-2032)
• Figure 32: Total Treated Cases of Endometriosis in Japan (2019-2032)
• Figure 33: Market Size of Endometriosis in the 7MM, USD million (2019-2032)
• Figure 34: Market Size of Endometriosis by Therapies in the 7MM, USD million (2019-2032)
• Figure 35: Market Size of Endometriosis in the US, USD million (2019-2032)
• Figure 36: Market Size of Endometriosis by Therapies in the US, USD million (2019-2032)
• Figure 37: Market Size of Endometriosis in EU4 and the UK, USD million (2019-2032)
• Figure 38: Market Size of Endometriosis by Therapies in EU4 and the UK, USD million (2019-2032)
• Figure 39: Market Size of Endometriosis in Japan, USD million (2019-2032)
• Figure 40: Market Size of Endometriosis by Therapies in Japan, USD million (2019-2032)
• Figure 41: Unmet Needs

DelveInsight's " Endometriosis - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the endometriosis, historical and forecasted epidemiology as well as the endometriosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The endometriosis market report provides current treatment practices, emerging drugs, endometriosis market share of the individual therapies, current and forecasted endometriosis market size from 2019 to 2032 segmented by seven major markets. The report also covers current endometriosis treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, Spain, Italy, and France)
• Japan

Study Period: 2019-2032

Endometriosis Understanding and Treatment Algorithm

The DelveInsight's Endometriosis market report gives a thorough understanding of the disease. Endometriosis is a disease distinguished by endometrial tissue outside the uterine cavity with recurrent intralesional bleeding because of the hormonal responsiveness of ectopic endometrial tissue, resulting in fibrosis. It is a disease of adolescents and reproductive-aged women commonly associated with chronic pelvic pain and infertility. The most common locations for endometriosis are the ovaries, pelvic peritoneum, uterosacral ligaments, and torus uterinus. Atypical pelvic endometriosis localizations can occur in the cervix, vagina, round ligaments, ureter, and nerves. Moreover, rare extrapelvic endometriosis implants can be localized in the upper abdomen, subphrenic fold, or abdominal wall.

The diagnosis of endometriosis has usually delayed an average of 4-11 years from the onset of symptoms due to the non-existence of a pathognomonic test or biomarker to detect the disease but also to the diversity of symptoms that could be considered physiologic responses during menstruation (like pain and discomfort) but also to the wide range of reported symptoms overlap with other gastrointestinal or gynecological causes. To achieve a proper diagnosis of endometriosis, the physician should start by taking a detailed history and performing a gynecological physical examination. The gold standard diagnostic tool remains laparoscopy, combined with an abdominal cavity exploration and a histological biopsy. However, ovarian endometrioma and deep nodular forms of the disease can be detected through ultrasonography and MRI.

Treatment

The management of endometriosis requires a multidisciplinary approach with surgical diagnosis and debulking of disease load, hormonal treatment to suppress and delay recurrence and progression of disease, pain management strategies best provided by a pain center clinic that develops individualized care plans, and pelvic therapy. Symptomatic endometriosis is typically treated by surgical or medical treatment, both equally effective. Despite the available associated pain treatments, endometriosis recurrence is not uncommon. Medical treatment choices are based on side effect profile, cost, and personal preference. Non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose combined oral contraceptive pills (COCPs) such as ethyl estradiol and progestins are the first choice drugs. If patients do not respond to NSAIDs in 3 months, the second line of treatments is used, which includes progestins (oral, injectable, and intra-uterine), androgens, and gonadotropin-releasing hormone agonists (GnRH), which reduce moderate-to-severe pain of endometriosis.

Endometriosis Epidemiology

The endometriosis epidemiology division provides insights about historical and current endometriosis patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides a historical as well as forecasted endometriosis epidemiology scenario in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.

In 2021, the total prevalent cases of endometriosis were ~ 21,920,000 in the 7MM, which are expected to grow during the study period, i.e., 2019-2032.

The disease epidemiology covered in the report provides historical as well as forecasted endometriosis epidemiology [segmented as Total Prevalent Cases of Endometriosis, Total Diagnosed Prevalent Cases of Endometriosis, Age-specific Diagnosed Prevalent Cases of Endometriosis, Diagnosed Prevalent Cases of Endometriosis by Pain Severity, and Total Treated Cases of Endometriosis] in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.

Country Wise- Endometriosis Epidemiology

The epidemiology segment also provides the endometriosis epidemiology data and findings across the United States, EU4 and the UK, and Japan.

Endometriosis Drug Chapters

The drug chapter segment of the endometriosis report encloses the detailed analysis of endometriosis marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the endometriosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for endometriosis treatment.

Endometriosis Market Outlook

Endometriosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted endometriosis market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the endometriosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the endometriosis market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

The Endometriosis market size in the 7MM is expected to change during the study period 2019-2032. The therapeutic market of endometriosis in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of endometriosis was ~USD 1,920 million which is expected to rise during the study period (2019-2032).

The United States Market Outlook

The total market size of endometriosis in the United States accounted for ~USD 1,190 million in 2021 which is expected to rise during the study period (2019-2032).

EU4 Countries and the UK: Market Outlook

In EU4 and the UK, the total market size of endometriosis was ~USD 590 million in 2021, which is expected to rise during the study period (2019-2032).

Japan Market Outlook

In Japan, the total market size of endometriosis was ~USD 130 million in 2021, which is expected to rise during the study period (2019-2032).

Endometriosis Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the endometriosis market or expected to get launched in the market during the study period 2019-2032. The analysis covers endometriosis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Endometriosis Development Activities

The report provides insights into different therapeutic candidates in the Phase II, and Phase III stages. It also analyses endometriosis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for endometriosis emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the endometriosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or endometriosis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the Endometriosia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of endometriosis explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the endometriosis epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for endometriosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the endometriosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global endometriosis market.

Report Highlights:

• In the coming years, the endometriosis market is set to change due to the upcoming therapies with the novel route of administrations which are under investigation and ongoing research in the endometriosis; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence endometriosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for endometriosis. The launch of emerging therapies will significantly impact the endometriosis market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for endometriosis.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Endometriosis Report Insights

• Patient Population
• Therapeutic Approaches
• Endometriosis Pipeline Analysis
• Endometriosis Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Endometriosis Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Endometriosis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Endometriosis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the endometriosis drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the endometriosis total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest endometriosis market size during the forecast period (2019-2032)?
• At what CAGR, the endometriosis market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the endometriosis market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the endometriosis market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of endometriosis?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 and the UK, and Japan?
• What is the historical endometriosis patient pool in seven major markets covering the United States, EU4 and the UK, and Japan?
• What would be the forecasted patient pool of endometriosis in seven major markets covering the United States, EU4 and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about endometriosis?
• Out of all 7MM countries, which country would have the highest prevalent population of endometriosis during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for endometriosis treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of endometriosis in the USA, Europe, and Japan?
• What are the endometriosis marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of endometriosis?
• How many therapies are in-development by each company for endometriosis treatment?
• How many are emerging therapies in mid-stage, and late stage of development for endometriosis treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the endometriosis therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for endometriosis and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for endometriosis?
• What are the global historical and forecasted markets of endometriosis?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the endometriosis market
• To understand the future market competition in the endometriosis market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for endometriosis in the US, EU4 and the UK, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the endometriosis market
• To understand the future market competition in the endometriosis market

Table of Contents

1. Key Insights

2. Report Introduction

3. Endometriosis Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Endometriosis in 2019
• 3.2. Market Share (%) Distribution of Endometriosis in 2032

4. Executive Summary of Endometriosis

• 4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

• 6.1. Introduction
• 6.2. Classification of Endometriosis
  • 6.2.1. American Society for reproductive medicine classification
  • 6.2.2. ENZIAN classification
  • 6.2.3. Endometriosis fertility index
  • 6.2.4. American Association of Gynecological Laparoscopists Classification
• 6.3. Types of Endometriosis
  • 6.3.1. Superficial peritoneal endometriosis
  • 6.3.2. Ovarian endometriosis
  • 6.3.3. Deep infiltrating endometriosis
• 6.4. Etiopathogenesis of Endometriosis
• 6.5. Risk Factors of Endometriosis
• 6.6. Symptoms of Endometriosis
• 6.7. Comorbidities of Endometriosis
  • 6.7.1. Gynecologic comorbidities
  • 6.7.2. Systemic comorbidities
• 6.8. Diagnosis of Endometriosis
  • 6.8.1. Patient and family history
  • 6.8.2. Physical examination
  • 6.8.3. Laparoscopy
  • 6.8.4. Imaging
  • 6.8.5. Serum markers
  • 6.8.6. Endometrial nerve fibers
  • 6.8.7. Diagnostic algorithm of endometriosis
  • 6.8.8. Differential diagnosis of endometriosis
  • 6.8.9. Diagnostic guidelines of endometriosis
• 6.9. Treatment of Endometriosis
  • 6.9.1. Hormonal treatments
  • 6.9.2. Nonhormone treatments
  • 6.9.3. Surgical treatment
  • 6.9.4. Treatment algorithm
  • 6.9.5. Treatment guidelines
• 6.1. Conclusion

7. Epidemiology and Patient Population

• 7.1. Key Findings
• 7.2. Assumptions and Rationale: The 7MM
• 7.3. Epidemiology Scenario in the 7MM
  • 7.3.1. Prevalent cases of endometriosis in the 7MM
  • 7.3.2. Diagnosed prevalent cases of endometriosis in the 7MM
  • 7.3.3. Age-specific diagnosed prevalent cases of endometriosis in the 7MM
  • 7.3.4. Diagnosed prevalent cases of endometriosis by pain severity in the 7MM
  • 7.3.5. Total treated cases of endometriosis in the 7MM
• 7.4. Epidemiology Scenario in the US
  • 7.4.1. Prevalent cases of endometriosis in the US
  • 7.4.2. Diagnosed prevalent cases of endometriosis in the US
  • 7.4.3. Age-specific diagnosed prevalent cases of endometriosis in the US
  • 7.4.4. Diagnosed prevalent cases of endometriosis by pain severity in the US
  • 7.4.5. Total treated cases of endometriosis in the US
• 7.5. Epidemiology Scenario in EU4 and the UK
  • 7.5.1. Prevalent cases of endometriosis in EU4 and the UK
  • 7.5.2. Diagnosed prevalent cases of endometriosis in EU4 and the UK
  • 7.5.3. Age-specific diagnosed prevalent cases of endometriosis in EU4 and the UK
  • 7.5.4. Diagnosed prevalent cases of endometriosis by pain severity in EU4 and the UK
  • 7.5.5. Total treated cases of endometriosis in EU4 and the UK
• 7.6. Epidemiology Scenario in Japan
  • 7.6.1. Prevalent cases of endometriosis in Japan
  • 7.6.2. Diagnosed prevalent cases of endometriosis in Japan
  • 7.6.3. Age-specific diagnosed prevalent cases of endometriosis in Japan
  • 7.6.4. Diagnosed prevalent cases of endometriosis by pain severity in Japan
  • 7.6.5. Total treated cases of endometriosis in Japan

8. Patient Journey

9. Key Endpoints in Endometriosis Clinical Trials

10. Marketed Therapies

• 10.1. Key Cross of Marketed Therapies
• 10.2. ORILISSA (elagolix): AbbVie
  • 10.2.1. Product description
  • 10.2.2. Regulatory milestones
  • 10.2.3. Other developmental activities
  • 10.2.4. Pivotal clinical trial
  • 10.2.5. Ongoing pipeline activity
• 10.3. MYFEMBREE (relugolix, estradiol, and norethindrone acetate): Myovant/Pfizer
  • 10.3.1. Product description
  • 10.3.2. Regulatory milestones
  • 10.3.3. Other developmental activities
  • 10.3.4. Pivotal clinical trial
  • 10.3.5. Ongoing pipeline activity
• 10.4. RELUMINA (relugolix): ASKA Pharmaceutical
  • 10.4.1. Product description
  • 10.4.2. Regulatory milestones
  • 10.4.3. Other developmental activities
  • 10.4.4. Pivotal clinical trial

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
  • 11.2.1. Product description
  • 11.2.2. Clinical developmental activities
• 11.3. Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals
  • 11.3.1. Product description
  • 11.3.2. Other developmental activities
  • 11.3.3. Clinical developmental activities
  • 11.3.4. Safety and efficacy
• 11.4. OVAREST (leuprorelin oral): SWK/Enteris BioPharma
  • 11.4.1. Product Description
  • 11.4.2. Other developmental activities
  • 11.4.3. Clinical developmental activities
  • 11.4.4. Safety and efficacy
• 11.5. HMI-115: Bayer/Hope Medicine
  • 11.5.1. Product description
  • 11.5.2. Other developmental activities
  • 11.5.3. Clinical developmental activities
• 11.6. TU2670 (NCE-403): Tiumbio
  • 11.6.1. Product description
  • 11.6.2. Clinical developmental activities
  • 11.6.3. Safety and efficacy
• 11.7. OG-6219: Organon
  • 11.7.1. Product description
  • 11.7.2. Other developmental activities
  • 11.7.3. Clinical developmental activities
  • 11.7.4. Safety and efficacy

12. Endometriosis: 7 Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Key Market Forecast Assumptions
• 12.4. Market Size in the 7MM
  • 12.4.1. Total market size of endometriosis in the 7MM
  • 12.4.2. Market size of endometriosis by therapies in the 7MM
• 12.5. The United States Market Size
  • 12.5.1. Total market size of endometriosis in the US
  • 12.5.2. Market size of endometriosis by therapies in the US
• 12.6. EU4 and the UK Market Size
  • 12.6.1. Total market size of endometriosis in EU4 and the UK
  • 12.6.2. Market size of endometriosis by therapies in EU4 and the UK
• 12.7. Japan Market Size
  • 12.7.1. Total market size of endometriosis in Japan
  • 12.7.2. Market size of endometriosis by therapies in Japan

13. Market Access and Reimbursement

• 13.1. Key HTA Decisions for Endometriosis
• 13.2. Patient Access Programs

14. KOL Views

15. SWOT Analysis

16. Unmet needs

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight